Evidence map›Paper›PMID 35772925›Full record

ArticleGut2023

Refining genetic and molecular classifications to facilitate breakthrough treatments in intrahepatic cholangiocarcinoma: are we there yet?

Satoru Morita, Dan G Duda

Abstract readComment
In one paragraph

Article in Gut, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Satoru MoritaRadiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-5551-8662
Dan G DudaRadiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA duda@steele.mgh.harvard.edu.ORCID 0000-0001-7065-8797

Funding

A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC PatientsR01CA260872 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AMIN, HESHAM M, DUDA, DAN GABRIEL · 2021 to 2025
$3.0M
Multiplexed time domain fluorescence tomography of tumor biomarkers during immunotherapyR01CA260857 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Dan Gabriel Duda, Anand T.N. Kumar · 2021 to 2026
$2.7M
Vascularized tumor explants for drug testingR01CA247441 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI MUNN, LANCE L. · 2021 to 2025
$1.9M
Radiation and CSPG4-specifc CAR T cell based combinatorial therapy for the in vivo treatment of TNBCR03CA256764 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI DUDA, DAN GABRIEL, WANG, XINHUI · 2021 to 2022
$167k
NCI NIH HHS R01 CA247441NCI NIH HHS R01 CA260857NCI NIH HHS R01 CA260872NCI NIH HHS R03 CA256764
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaBile Ducts, IntrahepaticHumansCHOLANGIOCARCINOMAIMMUNOLOGY

Identifiers

PMID35772925
PMCPMC10435277

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.